Value Sense
ELVN
Enliven Therapeutics, Inc. (ELVN)
Last Price$20.72.1%
Market Cap$972.8M
DCF value
N/A
Overvalued (DCF value)
(100.0%)
Discount Rate
9.6%
Long-Term Growth Rate
3.0%
Stock quality
6/10
Good
ELVN
is 28.2% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

ELVN DCF Model

Free Cash Flow to Firm Model
NOPAT Model
Free Cash Flow to Equity Model
Net Income Model
Millions
Billions
Dec'19 ActualDec'20 ActualDec'21 ActualDec'22 ActualDec'23 ActualDec'24 EstimateDec'25 EstimateDec'26 EstimateDec'27 EstimateDec'28 EstimateDec'29 EstimateDec'30 EstimateDec'31 EstimateDec'32 EstimateDec'33 EstimateDec'34 Terminal
Revenue
% growth
0.0
(100.0%)
0.0
(100.0%)
0.0
(100.0%)
0.0
(100.0%)
0.0
(100.0%)
0.0
(100.0%)
0.0
(833,400.0%)
0.0
20.0%
0.0
25.0%
0.0
93,240.8%
0.0
77,701.2%
0.0
62,161.5%
0.0
46,621.9%
0.0
31,082.3%
0.0
15,542.6%
0.0
3.0%
Operating income (EBIT)
% margin
(24.1)
0.0%
(9.3)
0.0%
(24.8)
0.0%
(38.8)
0.0%
(83.5)
0.0%
0.0
N/A
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
NOPAT
% effective tax rate
(24.8)
N/A
(9.3)
N/A
(24.7)
N/A
(38.9)
N/A
(83.5)
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
D&A
% of revenue
0.0
N/A
0.1
N/A
0.1
N/A
0.2
N/A
0.3
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
Capex
% of revenue
(0.1)
N/A
(0.5)
N/A
(0.2)
N/A
(0.6)
N/A
(0.1)
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
Change in Working Capital
% of revenue
0.7
N/A
0.6
N/A
3.6
N/A
0.4
N/A
1.4
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
Free Cash Flow to Firm (FCFF)
% of revenue
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
0.0
N/A
% of FCFF used in calculation
100.0%
80.8%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Discount period
0.50
1.50
2.50
3.50
4.50
5.50
6.50
7.50
8.50
Discount factor
0.96
0.87
0.80
0.73
0.66
0.61
0.55
0.50
0.46
Discounted FCFF (DFCFF)

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

ELVN DCF Value

DCF Value Calculation

as of Mar 11, 2025
Sum of DFCFF
% share of EV
N/A
30.0%
Terminal Value (TV)
N/A
Discounted TV
% share of EV
N/A
70.0%
Enterprise Value (EV)
0.0
Cash & Short-term Investments
253.1M
Total Debt
335.0K
Equity Value
N/A
Shares outstanding
47.0M
FX rate
N/A
DCF Value
N/A
100% overvalued

Equity Value Bridge

ELVN DCF Financials

Revenue
$0.0 -> $0.0 N/A CAGR
Operating Income
($83.5M) -> $0.0 (100.0%) CAGR
FCFF
N/A -> N/A N/A CAGR

ELVN DCF sensitivity

DCF value
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
9.0%
$0.0
$0.0
$0.0
$0.0
$0.0
9.5%
$0.0
$0.0
$0.0
$0.0
$0.0
9.6%
$0.0
$0.0
$0.0
$0.0
$0.0
10.5%
$0.0
$0.0
$0.0
$0.0
$0.0
11.0%
$0.0
$0.0
$0.0
$0.0
$0.0
DCF value, undervalued / overvalued
Long-term Terminal growth rate
2.0%
2.5%
3.0%
3.5%
4.0%
WACC
9.0%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
9.5%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
9.6%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
10.5%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)
11.0%
(100.0%)
(100.0%)
(100.0%)
(100.0%)
(100.0%)

Explore more intrinsic value tools hub for ELVN

Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF

FAQ

What is Enliven Therapeutics, Inc. DCF (discounted cash flow) valuation?

As of Mar 11, 2025, Enliven Therapeutics, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by (100.0%) compared to its current price of around $20.7, using a WACC of 9.6% and growth rates of 3.0%.

What is Enliven Therapeutics, Inc. WACC?

As of Mar 11, 2025, Enliven Therapeutics, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 9.6%.

What is Enliven Therapeutics, Inc. Enterprise Value?

As of Mar 11, 2025, Enliven Therapeutics, Inc.'s Enterprise Value (EV) is approximately $0.0. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.